Analysis of an ankyrin-like region in Epstein Barr Virus encoded (EBV) BZLF-1 (ZEBRA) protein: implications for interactions with NF-κB and p53
© Dreyfus et al; licensee BioMed Central Ltd. 2011
Received: 3 March 2011
Accepted: 5 September 2011
Published: 5 September 2011
The carboxyl terminal of Epstein-Barr virus (EBV) ZEBRA protein (also termed BZLF-1 encoded replication protein Zta or ZEBRA) binds to both NF-κB and p53. The authors have previously suggested that this interaction results from an ankyrin-like region of the ZEBRA protein since ankyrin proteins such as IκB interact with NF-κB and p53 proteins. These interactions may play a role in immunopathology and viral carcinogenesis in B lymphocytes as well as other cell types transiently infected by EBV such as T lymphocytes, macrophages and epithelial cells.
Randomization of the ZEBRA terminal amino acid sequence followed by statistical analysis suggest that the ZEBRA carboxyl terminus is most closely related to ankyrins of the invertebrate cactus IκB-like protein. This observation is consistent with an ancient origin of ZEBRA resulting from a recombination event between an ankyrin regulatory protein and a fos/jun DNA binding factor. In silico modeling of the partially solved ZEBRA carboxyl terminus structure using PyMOL software demonstrate that the carboxyl terminus region of ZEBRA can form a polymorphic structure termed ZANK (ZEBRA ANKyrin-like region) similar to two adjacent IκB ankyrin domains.
Viral capture of an ankyrin-like domain provides a mechanism for ZEBRA binding to proteins in the NF-κB and p53 transcription factor families, and also provides support for a process termed "Ping-Pong Evolution" in which DNA viruses such as EBV are formed by exchange of information with the host genome. An amino acid polymorphism in the ZANK region is identified in ZEBRA from tumor cell lines including Akata that could alter binding of Akata ZEBRA to the p53 tumor suppressor and other ankyrin binding protein, and a novel model of antagonistic binding interactions between ZANK and the DNA binding regions of ZEBRA is suggested that may be explored in further biochemical and molecular biological models of viral replication.
Keywordsp53 NF-κB transcription ankyrin phylogeny oncogenes viral carcinogenesis viral conditioning epi-genomics ping-pong evolution ASPP2 ASPP1 iASPP
Analysis of viruses, mobile DNA sequences and host genomes reveals evidence that genetic information can be shared resulting in generation of novel hybrid genetic elements. For example, the ubiquitous human pathogen Epstein Barr Virus (EBV), genome structure contains a region co-linear with the vertebrate variable immunoglobulin gene segments including regulatory regions for the myc oncogene, signals for immunoglobulin switch recombination, somatic mutation and coding regions[1, 2]. Similarly, the EBV viral termini contain sequences similar to somatic V(D)J immunoglobulin and T cell receptor recombination sites and the virus encodes a recombinase co-regulated with the host RAG V(D)J recombinase [3–5].
These observations suggest that EBV and other DNA viruses evolve through sharing of genetic information with the host genome termed "Ping Pong Evolution" [1, 2]. In this work, a remarkable example of Ping Pong Evolution between EBV and the host immune system is characterized. The EBV viral protein ZEBRA, Zta encoded by BZLF-1is proposed to result from capture and fusion of exons from two different host immune response genes, the fos/jun transcription factor and IκB immune regulatory proteins. Analysis of host IκB proteins is utilized to present an empirically testable model of ZEBRA binding to NF-κB immune response proteins in which the unstructured carboxyl region of ZEBRA can assume two different structural conformations when bound to NF-κB. In addition, an amino acid polymorphism in this region of ZEBRA is identified that could potentially alter the functional properties of the ZEBRA protein interactions with both NF-κB and the distantly related tumor suppressor p53.
Studies of ZEBRA, the lytic switch protein, have demonstrated that the two amino terminal exons of ZEBRA are structurally related to the fos/jun transcription factors and that ZEBRA binding to DNA sites, known as ZRE, is sufficient to activate the viral lytic cycle[7, 8]. The carboxyl region of ZEBRA protein can bind to components of the NF-κB transcription family in vitro and alter NF-κB transcription in vivo[9, 10]. Inactivation of NF-κB transcription is apparently independent of ZEBRA's ability to function as a transcription factor [11–13]. It is not currently known which of these multiple effects of ZEBRA contribute to viral carcinogenesis in a humanized mouse model .
One potential outcome of these interactions is that inactivation of NF-κB transcription during viral lytic replication confers a selective advantage upon the virus [15, 16]. NF-κB transcription factors and regulatory IκB proteins are central mediators of both the innate and acquired immune responses [17, 18]. Inactivation of NF-κB could block the innate immune response in B lymphocytes which are the viral host cell. Interaction between ZEBRA and NF-κB can trigger apoptosis of cells expressing ZEBRA [19–21]. Inactivation NF-κB transcription by ZEBRA in host B lymphocytes may also oppose the effects of latency proteins that activate NF-κB transcription, delaying apoptosis and contributing to viral maturation and release from pre-apoptotic host cells.
Other bystander cells such as T-lymphocytes, epithelial cells and macrophages may also be transiently infected with EBV. T lymphocytes in particular express both the EBV CD21 receptor as well as other EBV receptors and express ZEBRA protein [3, 21, 22]. Studies of the effects of transient and stable expression of ZEBRA in T-lymphoblastoid cell lines have confirmed an IκB-like inactivation NF-κB signaling by ZEBRA and increased T lymphocyte apoptosis . Thus, an additional selective advantage of interactions between ZEBRA and NF-κB may be destruction of immune responder cells through transient infection and apoptosis.
Another human gamma herpesvirus, human herpesvirus-8, first identified as the cause of Kaposi's sarcoma, encodes a lytic replication protein which lacks DNA binding but has extensive amino acid similarity to ZEBRA including the carboxyl region of ZEBRA [23–25]. This region of ZEBRA is highly conserved between different viral strains . EBV infected lymphocytes also express a trans-spliced ZEBRA like protein termed RAZ sharing the carboxyl terminal NF-κB binding region of the ZEBRA protein, but lacking the ability to bind DNA or ZRE[15, 27]. RAZ is also expressed in EBV infected T lymphocytes[3, 22].
Remarkably, the carboxyl region of ZEBRA required for interactions with NF-κB transcription and ZEBRA dimerization also binds to p53 tumor suppressor in vitro and alters p53 transcription in vitro[28–30]. The effects of ZEBRA on p53 transcription are stimulatory in some cases such as T-lymphocytes and epithelial cells, but inhibitory in B-lymphocytes[29, 30]. Interactions between ZEBRA and p53 also involve other p53 binding proteins and are more complex than interactions in vivo between ZEBRA and NF-κB . The ability of ZEBRA to interact with both NF-κB and p53 has previously been suggested to result from a cryptic IκB-like region in the carboxyl terminus of the ZEBRA protein[6, 21]. NF-κB and p53 proteins share a common IκB binding region because they are descendents of a common ancestral transcription factor previously termed "proto p53/NF-κB". Since this hypothesis was proposed, the crystal structure of ZEBRA protein has been partially solved including a portion of the carboxyl terminus of the protein interacting with NF-κB and p53[8, 32]. In addition, the interactions between p53 binding ankyrin proteins and NF-κB proteins have been characterized providing additional evidence that regulatory proteins in the ankyrin family, including NF-κB inhibitor proteins related to IκB, bind to both NF-κB and p53 proteins.
The recently available partial structure of the ZEBRA carboxyl terminus, and the structures of IκBα and apoptosis-stimulating protein of p53 (ASPP2, previously known as p53BP2) ankyrin proteins are analyzed in this work, building on previous similarities noted between these regulatory proteins. First, it is demonstrated that primary amino acid similarities between the alpha helix regions of ZEBRA and various other ankyrin proteins are unlikely to have arisen by chance or independent parallel evolution but instead appear to represent capture and homologous descent of a terminal exon encoding an IκB domain by ZEBRA. Second, it is shown that the partial crystal structure of ZEBRA is consistent with dimerization of the terminal region of the protein to form an IκB-like stem and loop structure. Finally, individual ankyrin domains of IκBα are shown to have structural similarities to the ankyrins of ASPP2, and thus able to bind to the same region targeted by ZEBRA.
Definition of the ankyrin-like region of ZEBRA protein termed "ZANK"
Alignment of ZANK with defined ankyrin proteins
Randomization analysis of ZANK and other defined ankyrin domains
Based on these studies the similarity between putative ZEBRA ankyrin stem and the cactus ankyrin stems 4 is one order of magnitude greater than other ankyrin stems, and this relationship was maintained over a variety of Price Waterman gap values. Also highly unlikely to occur by chance are the alignments between the putative ZEBRA ankyrin stem and the cactus stem 2 and Bcl3 ankyrin 4 stem. In many cases individual ankyrin stems from different ankyrin proteins such as invertebrate cactus, IκB and p53 binding protein were more closely related than adjacent ankyrins from a single protein, for example cactus ankyrin stem 4 and bcl3 ankyrin stem 4 are more similar than cactus ankyrin stem 4 and other cactus ankyrins (BCL3 data not shown). Based upon randomized sequence comparisons shown in the ZEBRA stem-like region is most similar to the stem region 4 of a Cactus ankyrin from the Drosophila fruit fly. Interestingly, the loop region of ZEBRA is most similar to a different loop region from the cactus protein, ankyrin 5 of cactus. However, because of the short length o the ZEBRA stem region and other confounding factors such as apparent functional constraints on stem sequence evolution it was not possible to construct a unique rooted phylogeny of individual ankyrin stems using currently available alignment software (data not shown).
Visual inspection of individual ankyrin stem and loop regions (Figure 5) also suggests that the loop regions of all of the cellular ankyrins were less significantly related either to ZEBRA or to each other except in the stem regions. In addition, IκB and cactus ankyrins follow a pattern where alternating ankyrin loops are similar between odd and even numbered repeats, for example ankyrin 3 and 5 loops have more similarity in both amino acid composition and length than to ankyrins 2 and 4 loops from both IκB and cactus. Relationships between individual ankyrin stems and loops thus appear to represent a complicated mixture of functional constraints operating independently of evolutionary descent and shared sequences conserved through descent from a common precursor as will be analyzed in more detail elsewhere.
In silico modeling of structural similarities between ZANK and other defined ankyrin domains
Protein data based files of ZEBRA (2C9N.pdb), IκB bound to NF-κB protein p65 (1lKN.pdb), and the p53BP2 fragment of ASPP2 (1YCS.pdb) were used to generate PyMOL based alignments. Experimentally determined structures were aligned using the "align" feature of PyMOL without any operator adjustments and using molecular coordinates as deposited in respective pdb files without alteration of molecular coordinates. ZANK was superimposed upon adjacent ankyrin domains of the IκBα protein initially solved as a complex with NF-κB p65 and the p53BP2 fragment of ASPP2 p53 binding protein solved as a complex with p53 (p53 structure not shown). A mechanism is proposed consistent with the partial structure of ZANK suggesting that the observed structure of ZANK could act as a dimorphic dimer and interact with adjacent dimorphic regions of NF-κB, and also related ankyrin binding regions of p53. IκBα and IκBα and p53 binding ankyrin proteins, although not identical in primary amino acid sequence, have remarkably similar interactions with NF-κB protein. This analysis is also used to suggest a testable hypothesis where an amino acid polymorphism previously identified between ZEBRA protein from Akata tumor cells and the ZEBRA protein from non-tumorigenic B-958 could modulate the binding interactions between ZEBRA and p53 leading to a more cancer-promoting viral phenotype in the case of the Akata derived ZEBRA.
Identification of a structural and functional divergence between ZEBRA carboxyl terminus and fos/jun transcription factors
Epstein Barr Virus (EBV) encoded ZEBRA protein is capable of switching the viral state from latency to lytic growth through its effects on specific DNA binding sites termed ZRE (ZEBRA Response Elements). The crystal structure of the protein bound to a ZRE oligonucleotide reveals similarity to Fos/Jun and other DNA binding proteins of the BZIP transcription family as expected from similarities between ZRE and AP-1 binding sites. The structure of the carboxyl terminal region of the ZEBRA protein has not been determined in the published crystal structure as inclusion of this region prevented protein crystallization suggesting a disordered structure (Figure 1) . This region of ZEBRA is also dispensable for DNA binding.
Efforts to discover a specific mechanism for protein-protein interactions of the carboxyl terminus region of ZEBRA based upon the partially solved structure have been unsuccessful, although some similarities are evident between this region and C/EBP-α, a CAAT-binding transcription factor whose dysregulation is implicated in acute myeloid leukemia . Notably, the conserved carboxyl terminus of ZEBRA (Figure 2) diverges from DNA binding proteins of the BZIP family precisely at the intron border of exon 3 (Figure 3). Like the ZEBRA terminal exon, IκB binds to both p53 and NF-κB [6, 21]. Exon 1 and 2 of ZEBRA thus encode a Fos/Jun homologue that activates DNA transcription to initiate the viral lytic program, while exon 3 (shared with trans-spliced RAZ protein) provides both protein self-dimerization and binding to other master regulatory transcription factors such as p53 and NF-κB. These observations are analyzed in more detail in the remainder of this work.
ZANK, the carboxyl terminal Zebra ANKyrin-like region
Interactions between ZEBRA and NF-κB, p53 as well as other proteins can occur independently of ZEBRA DNA binding, since experiments in vivo have shown that in T-lymphocytes ZEBRA is not bound to DNA but localized to the cytoplasm where it blocks NF-κB translocation to the nucleus [6, 21]. The full sequence of the carboxyl terminus exon (exon 3) of ZEBRA is shown in Figure 2, including both regions of the protein present in the crystal structure (blue highlights in Figure 1) and extreme carboxyl residues not present in the crystal structure . We previously suggested that the carboxyl terminus of ZEBRA encodes an ankyrin-like structure responsible for the ability of ZEBRA to bind ankyrin binding proteins NF-κB and p53 [6, 21]. For purposes of discussion, the carboxyl terminus of ZEBRA encoded by exon 3 is termed ZANK (for ZEBRA ANKyrin-like region) in the remainder of this work. Remarkably, the crystal structure of ZEBRA protein (Figure 1) shows divergence from BZIP Fos/Jun DNA binding proteins precisely at the intron/exon borders of ZEBRA exon 3 (Figure 2, 3).
Comparison of ZANK with defined vertebrate and invertebrate ankyrin domains
ZANK spans part of the alpha helix of ZEBRA and unstructured regions at the carboxyl terminus of the protein (Figure 3, 4). The alpha-helical stem-like regions contribute most of the similarity between ZANK and individual ankyrins (Figure 5). This is evident in Figure 5 because most of the colored coded similar regions occur to the left of the figure in the stem regions (denoted s) rather than the loop regions (denoted l). This was confirmed by a randomization analysis (Figure 6). Randomizations demonstrate that the full ZANK sequence or loop region results in less significant alignments or no significant alignments for both ZANK and other ankyrins compared to randomization of the stem regions (Figure 6). The alpha helical regions of ankyrin binding proteins are highly structured to provide a rigid framework, while the loop regions are less structured allowing for binding to different substrates. Results are consistent with the hypothesis that ZANK encodes amino acids derived from a common ancestral ankyrin domain shared with IκB and p53 binding ankyrins and are most closely related to the invertebrate Drosophila ankyrin regulatory protein Cactus, rather than vertebrate ankyrins.
Statistical significance as highlighted in yellow in Figure 6 is defined as a given alignment found in less than 5% of shuffled sequences (less than 500 out of 10,000), corresponding to P < 0.05 that the alignment would occur by chance. A more stringent definition of a non-random alignment (highlighted in red in Figure 6) is defined as a given alignment found in less than 0.1% of shuffled sequences (less than 10 out of 10,000). In all cases analyzed, including ZANK, the stem or alpha helix regions of ankyrins are more conserved across ankyrin protein families than the loop regions. For example, not all IκBα loops in host proteins are similar to each other, but all the IκBα stem regions are similar based upon 10,000 random shuffling of the respective sequences.
The diagonal of each randomization experiment shown is the identity of the sequence with itself shown in red, which as expected, occurs once per 10,000 shuffling experiments. Because each cell represents a characterization of an independent shuffling "experiment" the number of aligned sequences are slightly different even for identical comparisons as can be seen by comparing identical comparisons on either side of the diagonal identity but because of the large number of shuffling per "experiment" results are usually similar for a given cell on either side of the diagonal.
ZANK is more similar to an invertebrate ankyrin domain from Cactus than vertebrate ankyrins
As shown in Figure 6, the ZANK stem was most similar to the ankyrin 4 stem region of invertebrate Drosophila Cactus regulatory protein at the highest level of significance (less than 10/10,000 of shuffled sequences). ZANK loop was most similar to invertebrate Drosophila Cactus regulatory protein ankyrin 5 loop region at the highest level of significance (less than 10/10,000 of shuffled sequences). Similarity was also evident between ZANK and the Cactus regulatory protein ankyrin 2 stem region and the IκBα ankyrin 3 and 5 stems as well as the whole protein. Similarity to both stem and loop regions of Cactus in addition to elements of IκBα is a surprising result since EBV is a vertebrate pathogen, while Cactus is an invertebrate host gene, suggesting that the divergence of ZANK from other ankyrins was ancient, possibly preceding divergence of p53 and NF-κB ankyrin binding proteins such as IκBα. Alternatively, a vertebrate virus encoding ZANK could have resulted from recombination with an invertebrate Drosophila virus since in some cases insect viruses can infect vertebrate cells. Existing phylogeny programs do not appear able to resolve these two possibilities as will be discussed in more detail elsewhere.
In silico Modeling of ZANK
In the remainder of this work we used PyMOL generated structures to model experimentally observed binding between ZEBRA protein and both NF-κB and p53 in vitro and in vivo. A limitation of this analysis is that the existing structure of ZANK is both partial and also solved in the absence of the partner ligands p53 or NF-κB. However, even with those limitations this analysis is sufficient to suggest a model of ZANK interactions with its partner ligands in which the ZANK loop adopts two different conformations. We have previously suggested that binding between ZEBRA carboxyl terminus and other proteins can be explained by the common descent of both NF-κB and p53 from an ancestral protein termed proto-p53/NF-κB. If this hypothesis is correct then it should be possible to identify a common structural signature or code between ZANK, NF-κB binding ankyrins and p53 binding ankyrins that ZANK has evolved to fit into. To use an analogy, if ankyrins resemble a key that can bind to their substrates resembling a lock, then the ZANK key should fit into both the NF-κB and p53 locks[6, 21].
NF-κB binding ankyrins have an alternating key or code of short and long ankyrin loops suggesting a polymorphic ZANK loop domain
Also resulting from this alternating short loop/long loop pattern, using PyMOL generated structures it is evident that IκBα ankyrin 3 has additional amino acids in its loop region forming a bulge not present in ankyrin 4, and also has hydrophobic amino acids in its loop not present in ankyrin 4 (Figure 9). If ZEBRA were to bind to both IκBα ankyrin 3 and 4 binding regions in NF-κB, ZANK would need to adapt 2 different conformations to fit into the two different sites, for example by having free amino acids outside of the binding region at the Ankyrin 4 site, while utilizing additional amino acids in the extreme carboxyl region of the ZEBRA protein in the deeper Ankyrin 3 site. The bulge region present both ankyrin 3 and 5 loops is not present in ankyrin 4 loop (Figure 10), but corresponds to a structured region of the ZANK loop (Figure 9). In the IκBα structure, these structured regions of are proposed to form a α helix like region stabilizing the IκBα loops.
Shared structural elements between p53 and NF-kB binding ankyrins identified as a potential binding mechanism of ZANK
Identification of a cancer associated sequence variant in ZANK potentially altering p53binding interactions
A model of antagonistic interactions between ZANK NF-κB and p53 protein binding and ZEBRA fos/jun DNA binding
Binding of ZANK to proteins of the NF-κB and p53 families could stimulate, inhibit or have no effect of ZEBRA binding to DNA. As shown in Figure 13, structural considerations based on the partial structure of ZEBRA and ZANK support an antagonistic role between ZEBRA DNA binding and ZANK interactions with NF-κB and p53 proteins. Based upon the crystal structure of ZEBRA bound to a ZRE/AP1 DNA binding oligonucleotide (Figure 1), it is apparent that DNA bound to ZEBRA causes the two DNA binding alpha helices to move away from each other. The movement of the ZANK regions at the termini of the helices in a region not bound to DNA is analogous to the blades of a scissor in the open position. A parallel orientation of the ZANK stems, similar to the closed blades of a scissor is required to form an ankyrin-like dimer capable of binding adjacent regions of NF-κB and p53 proteins (Figure 7).
Thus, ZANK could function as a NF-κB and p53 protein dependent switch in the nucleus of EBV infected B-lymphocytes, turning ZEBRA DNA binding off in the presence of high levels of nuclear NF-κB and p53, and conversely activating ZEBRA DNA binding in the absence of nuclear NF-κB and p53 protein (Figure 13). In physiologic terms, these observations are consistent with high levels of active NF-κB and p53 proteins present in the nucleus of latent B-lymphocytes during viral latency, which during viral latency would tend to block ZEBRA DNA binding and prevent activation of viral lytic growth. Conversely, transiently decreased levels of nuclear NF-κB proteins in latently infected B-lymphocytes, due for example to cell stress or starvation could permit increased ZEBRA DNA binding and activation of viral lytic growth, coupling levels of cytoplasmic growth signals mediated by NF-κB and p53 proteins to the viral life cycle.
Later in the viral lytic replication cycle, the NF-κB and p53 protein binding function of ZANK could further trigger cellular apoptosis and facilitate infectious viral release directly through cytoplasmic effects on NF-κB and p53 protein. In T lymphocytes and possibly other non B-lymphocyte cells infected by EBV but incapable of supporting stable viral latency, ZEBRA is almost entirely present in the cell cytoplasm. In these cells, ZEBRA could initially inhibit NF-κB and cause activation of p53 protein and cellular apoptosis as a mechanism of viral immunosuppression.
Transpliced RAZ, containing ZANK but not capable of ZEBRA DNA binding would then serve as an amplifier of the NF-κB and p53 protein functions of ZEBRA, and a corresponding RAZ-like function might explain the non-DNA binding functions of a ZEBRA homologue in HSV-8, the etiologic agent of Kaposi's sarcoma and other human cancers. These possibilities could in principle be tested in vitro and in vivo through ZEBRA with ZANK domains engineered for either increased or reduced effects on NF-κB and/or p53 protein through mutation of conserved ZANK amino acids interacting with NF-κB and p53 protein identified with the structural models and analysis presented in this work.
Characterization of B cell lympho-proliferative disorders haa demonstrated that EBV viral latency proteins can transform and immortalize B-lymphocytes in vitro and in vivo. A causal role of the virus in carcinogenesis is suggested in some tumors because the viral genome sometimes remains in the malignant cell. However, the mechanism of viral carcinogenesis cannot simply be a function of cellular immortalization by the virus since although the vast majority of humans harbor EBV immortalized B lymphocytes, EBV-genome associated cancers are rare . EBV infection may thus also be associated with carcinogenesis not only through cellular immortalization but also through transient mechanisms including destabilization of host genomes[37–40].
A novel role of ZEBRA and ZANK in viral carcinogenesis is suggested in this work. ZEBRA plays a critical role in the viral latent to lytic switch, possibly in part through response to NF-κB and p53 activities by ZANK (Figure 13). Alternating cycles of partial lytic growth triggered by ZEBRA activation and ZEBRA DNA binding followed by ZANK interactions with NF-κB and p53 could synergize with genomic instability contributed by cellular or viral recombinase activation in EBV infected cells. Partial cycles of viral activation and inactivation without completion of the viral life cycle could be particularly relevant in the "hit and run" scenario, proposed for viral carcinogenesis and immune dysregulation as proposed in epithelial breast cancers [41–47].
Notably, it is possible that viral inactivation of p53 originates indirectly or as an evolutionary "spandrel." A spandrel refers to a new phenotype generated by alteration of a related developmental pathway. Because of the evolutionary relationship between NF-κB and p53 through descent from a common ancestral transcription factor, an unavoidable consequence of the inactivation of NF-κB by an ankyrin-like region of ZEBRA is a spandrel-like transient inactivation of p53. Restated, the common origins of NF-κB and p53 conserve a similar ankyrin binding region in both proteins, so any viral protein that targets this site on NF-κB proteins could, in parallel, affect p53 generating new p53 dependent phenotypes. This may in part contribute to the selective loss of the IκBα locus in tumors, a conserved feature of several EBV associated tumors[48, 49]. The ZANK spandrel effects on p53 are maintained because of a selective benefit to the virus from related transient inactivation of the NF-κB transcription family and the innate immune system, as well as effects of ZANK on regulation of ZEBRA DNA binding.
Mutant p53 proteins were first characterized as oncogenes because their presence was associated with tumor phenotypes including tumor growth and resistance to apoptosis[50–52]. Surprisingly, wild type p53 was later shown to be a tumor suppressor through the effects of the protein as a DNA-binding transcription factor, rather than a tumor promoter. These contradictory effects could result from opposing tumor promoting spandrel effects between numerous viral proteins such as ZEBRA and mutant p53 proteins, versus tumor suppressing DNA binding gene activation by wild type p53 protein. Thus ZANK might augment the effects of mutant p53, not directly related to p53 DNA binding, but rather due to effects on structurally similar regions of NF-κB proteins required for cellular proliferation.
From an evolutionary perspective, it is likely that EBV encoded ZEBRA protein and a related protein in Human Herpes Virus 8 diverged from other BZIP DNA binding proteins such as Fos/Jun through viral capture of a terminal exon encoding a single ankyrin-like stem and loop. This domain was capable of dimerization into a structure resembling adjacent IκB ankyrins, and was subject to positive selection through interactions with NF-κB proteins. However, because of the shared ankyrin binding domain between NF-κB and p53 proteins an unfortunate consequence of NF-κB inhibition by ZANK would also unavoidably be inactivation of p53. This could be particularly important as a pathogenic mechanism of EBV-related genomic instability in epithelial cells and T lymphocytes that do not support the establishment of viral latency or replication but can sustain a limited form a viral lytic growth that includes high levels of expression of a trans-spliced protein "RAZ" containing ZANK, but without the DNA-binding transcriptional activity on ZRE. In this context, these cells are "dead end hosts" in their inability to support viral replication but can nevertheless suffer the pathophysiological and molecular consequences of viral infection.
Viral pre-conditioning by common viral pathogens has been indirectly implicated in the clustering of human cancers both geographically and temporally based upon indirect evidence in human cancers that defective or abortive replication of common viral pathogens can account for clustering of cancers. In the "viral conditioning" scenario, abortive cycles of viral replication can promote genomic instability. A model is presented here for the specific case of EBV. In the case of EBV and, potentially, other common viruses that interact with both NF-κB and p53, transient lytic gene expression in both B lymphocytes and non-B cells could provide a mechanism for this viral pre-conditioning where defective or aborted viral replication contributes to malignancy as supported by indirect epidemiologic evidence[54–56]. These effects of ZANK could be of particular importance not only in B lymphocytes but in epithelial and T cell infection in which the virus expresses lytic gene products but in most cases does not establish latency. In these cell types transient inactivation of the tumor suppressor p53 would occur in the context of activation of endogenous somatic recombination pathways, potentially resulting in re-arrangement, instability and mutation of endogenous oncogenes.
In summary, we have demonstrated that ZEBRA is a hybrid protein resulting from viral capture of both a Fos/Jun like transcription factor and a polymorphic IκB-like ankyrin carboxyl terminus. Primary sequence and structural similarities are evident between the carboxyl terminus of ZEBRA protein and the conserved stem regions of IκBα and p53BP2/ASPP2 ankyrins. It is suggested that a shared binding pocket in NF-κB is in turn bound by all of these ankyrin proteins and that ZANK is analogous to a "master key" capable of fitting into both NF-κB and p53 protein "locks". In the case of ZEBRA, protein binding to NF-κB provides a selective advantage to the virus through inactivation of the immune response against the virus during viral lytic replication, simultaneously and unavoidably altering the activation of p53.
LYG would like to thank Dr. Leslie Krueger for helpful discussions regarding EBV "hit-and-run" hypothesis and Dr. David H. Wagner for conversations and ideas regarding NF-kappa B and other topics including autoimmunity. Dr. Dreyfus (DHD) has been supported in the past by NIH training grants T32-GM07288 and T32-AI07365. DHD acknowledges helpful discussions with Dr. Hans Helmut Niller, University of Regensburg, Germany, Jill Countryman, Yale School of Medicine, New Haven CT, and Dr. Cedric Feschote, University of Texas, Austin as well as members of the Weizmann Institute in Israel (in alphabetical order) Drs. Boris Brumshtein, Moshe Oren, Zippi Shakked and Joel Sussman. DHD and LYG are co-founders of a Keren Pharmaceutical Inc., San Mateo, CA. DHD is Assistant Clinical Professor, Department of Pediatrics, Yale School of Medicine, New Haven, CT and a member of the Center for Allergy, Asthma, and Clinical Immunology (CAAI), Waterbury, CT. and JC and YL are associated with Yale University, however none of the observations, proposals and/or conclusions of this work are related to the operations of Keren, Yale, or CAAI.
- Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Schwarzmann F, Wolf H, Minarovits J: EBV-associated neoplasms: alternative pathogenetic pathways. Med Hypotheses 2004, 62: 387-391. 10.1016/j.mehy.2003.11.001View ArticlePubMedGoogle Scholar
- Niller HH, Salamon D, Rahmann S, Ilg K, Koroknai A, Banati F, Schwarzmann F, Wolf H, Minarovits J: A 30 kb region of the Epstein-Barr virus genome is colinear with the rearranged human immunoglobulin gene loci: implications for a "ping-pong evolution" model for persisting viruses and their hosts. A review. Acta Microbiol Immunol Hung 2004, 51: 469-484. 10.1556/AMicr.51.2004.4.7View ArticlePubMedGoogle Scholar
- Dreyfus DH, Kelleher CA, Jones JF, Gelfand EW: Epstein-Barr virus infection of T cells: implications for altered T-lymphocyte activation, repertoire development and autoimmunity. Immunol Rev 1996, 152: 89-110. 10.1111/j.1600-065X.1996.tb00912.xView ArticlePubMedGoogle Scholar
- Dreyfus DH: Immune system: success owed to a virus? Science 2009, 325: 392-393.View ArticlePubMedGoogle Scholar
- Dreyfus DH: Paleo-immunology: evidence consistent with insertion of a primordial herpes virus-like element in the origins of acquired immunity. PLoS One 2009, 4: e5778. 10.1371/journal.pone.0005778PubMed CentralView ArticlePubMedGoogle Scholar
- Dreyfus DH, Nagasawa M, Gelfand EW, Ghoda LY: Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors. BMC Immunol 2005, 6: 12. 10.1186/1471-2172-6-12PubMed CentralView ArticlePubMedGoogle Scholar
- Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L: Lytic cycle switches of oncogenic human gammaherpesviruses. Adv Cancer Res 2007, 97: 81-109.View ArticlePubMedGoogle Scholar
- Petosa C, Morand P, Baudin F, Moulin M, Artero JB, Muller CW: Structural basis of lytic cycle activation by the Epstein-Barr virus ZEBRA protein. Mol Cell 2006, 21: 565-572. 10.1016/j.molcel.2006.01.006View ArticlePubMedGoogle Scholar
- Gutsch DE, Holley-Guthrie EA, Zhang Q, Stein B, Blanar MA, Baldwin AS, Kenney SC: The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol 1994, 14: 1939-1948.PubMed CentralView ArticlePubMedGoogle Scholar
- Morrison TE, Kenney SC: BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function. Virology 2004, 328: 219-232. 10.1016/j.virol.2004.07.020View ArticlePubMedGoogle Scholar
- Schelcher C, Al Mehairi S, Verrall E, Hope Q, Flower K, Bromley B, Woolfson DN, West MJ, Sinclair AJ: Atypical bZIP domain of viral transcription factor contributes to stability of dimer formation and transcriptional function. J Virol 2007, 81: 7149-7155. 10.1128/JVI.00215-07PubMed CentralView ArticlePubMedGoogle Scholar
- Schelcher C, Valencia S, Delecluse HJ, Hicks M, Sinclair AJ: Mutation of a single amino acid residue in the basic region of the Epstein-Barr virus (EBV) lytic cycle switch protein Zta (BZLF1) prevents reactivation of EBV from latency. J Virol 2005, 79: 13822-13828. 10.1128/JVI.79.21.13822-13828.2005PubMed CentralView ArticlePubMedGoogle Scholar
- McDonald CM, Petosa C, Farrell PJ: Interaction of Epstein-Barr virus BZLF1 C-terminal tail structure and core zipper is required for DNA replication but not for promoter transactivation. J Virol 2009, 83: 3397-3401. 10.1128/JVI.02500-08PubMed CentralView ArticlePubMedGoogle Scholar
- Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, et al.: A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011, 85: 165-177. 10.1128/JVI.01512-10PubMed CentralView ArticlePubMedGoogle Scholar
- Morrison TE, Mauser A, Wong A, Ting JP, Kenney SC: Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity 2001, 15: 787-799. 10.1016/S1074-7613(01)00226-6View ArticlePubMedGoogle Scholar
- Morrison TE, Mauser A, Klingelhutz A, Kenney SC: Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1. J Virol 2004, 78: 544-549. 10.1128/JVI.78.1.544-549.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Huxford T, Huang DB, Malek S, Ghosh G: The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 1998, 95: 759-770. 10.1016/S0092-8674(00)81699-2View ArticlePubMedGoogle Scholar
- Jacobs MD, Harrison SC: Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998, 95: 749-758. 10.1016/S0092-8674(00)81698-0View ArticlePubMedGoogle Scholar
- Kenney JL, Guinness ME, Curiel T, Lacy J: Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998, 92: 1721-1727.PubMedGoogle Scholar
- Feng WH, Westphal E, Mauser A, Raab-Traub N, Gulley ML, Busson P, Kenney SC: Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol 2002, 76: 10951-10959. 10.1128/JVI.76.21.10951-10959.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Dreyfus DH, Nagasawa M, Pratt JC, Kelleher CA, Gelfand EW: Inactivation of NF-kappaB by EBV BZLF-1-encoded ZEBRA protein in human T cells. J Immunol 1999, 163: 6261-6268.PubMedGoogle Scholar
- Kelleher CA, Paterson RK, Dreyfus DH, Streib JE, Xu JW, Takase K, Jones JF, Gelfand EW: Epstein-Barr virus replicative gene transcription during de novo infection of human thymocytes: simultaneous early expression of BZLF-1 and its repressor RAZ. Virology 1995, 208: 685-695. 10.1006/viro.1995.1200View ArticlePubMedGoogle Scholar
- Sinclair AJ: bZIP proteins of human gammaherpesviruses. J Gen Virol 2003, 84: 1941-1949. 10.1099/vir.0.19112-0View ArticlePubMedGoogle Scholar
- Sinclair AJ: Unexpected structure of Epstein-Barr virus lytic cycle activator Zta. Trends Microbiol 2006, 14: 289-291. 10.1016/j.tim.2006.05.003PubMed CentralView ArticlePubMedGoogle Scholar
- Al Mehairi S, Cerasoli E, Sinclair AJ: Investigation of the multimerization region of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) protein K-bZIP: the proposed leucine zipper region encodes a multimerization domain with an unusual structure. J Virol 2005, 79: 7905-7910. 10.1128/JVI.79.12.7905-7910.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Packham G, Brimmell M, Cook D, Sinclair AJ, Farrell PJ: Strain variation in Epstein-Barr virus immediate early genes. Virology 1993, 192: 541-550. 10.1006/viro.1993.1070View ArticlePubMedGoogle Scholar
- Furnari FB, Zacny V, Quinlivan EB, Kenney S, Pagano JS: RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism. J Virol 1994, 68: 1827-1836.PubMed CentralPubMedGoogle Scholar
- Zhang Q, Gutsch D, Kenney S: Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 1994, 14: 1929-1938.PubMed CentralView ArticlePubMedGoogle Scholar
- Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S: The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol 2002, 76: 12503-12512. 10.1128/JVI.76.24.12503-12512.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Dreyfus DH, Nagasawa M, Kelleher CA, Gelfand EW: Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. Blood 2000, 96: 625-634.PubMedGoogle Scholar
- Bailey SG, Verrall E, Schelcher C, Rhie A, Doherty AJ, Sinclair AJ: Functional interaction between Epstein-Barr virus replication protein Zta and host DNA damage response protein 53BP1. J Virol 2009, 83: 11116-11122. 10.1128/JVI.00512-09PubMed CentralView ArticlePubMedGoogle Scholar
- Hicks MR, Balesaria S, Medina-Palazon C, Pandya MJ, Woolfson DN, Sinclair AJ: Biophysical analysis of natural variants of the multimerization region of Epstein-Barr virus lytic-switch protein BZLF1. J Virol 2001, 75: 5381-5384. 10.1128/JVI.75.11.5381-5384.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Benyamini H, Leonov H, Rotem S, Katz C, Arkin IT, Friedler A: A model for the interaction between NF-kappa-B and ASPP2 suggests an I-kappa-B-like binding mechanism. Proteins 2009, 77: 602-611. 10.1002/prot.22473View ArticlePubMedGoogle Scholar
- Ahn J, Byeon IJ, Byeon CH, Gronenborn AM: Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J Biol Chem 2009, 284: 13812-13822. 10.1074/jbc.M808821200PubMed CentralView ArticlePubMedGoogle Scholar
- El-Guindy AS, Paek SY, Countryman J, Miller G: Identification of constitutive phosphorylation sites on the Epstein-Barr virus ZEBRA protein. J Biol Chem 2006, 281: 3085-3095.View ArticlePubMedGoogle Scholar
- Thorley-Lawson DA: EBV the prototypical human tumor virus--just how bad is it? J Allergy Clin Immunol 2005, 116: 251-261. quiz 262 10.1016/j.jaci.2005.05.038View ArticlePubMedGoogle Scholar
- Niller HH, Salamon D, Uhlig J, Ranf S, Granz M, Schwarzmann F, Wolf H, Minarovits J: Nucleoprotein structure of immediate-early promoters Zp and Rp and of oriLyt of latent Epstein-Barr virus genomes. J Virol 2002, 76: 4113-4118. 10.1128/JVI.76.8.4113-4118.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Niller HH, Wolf H, Minarovits J: Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009, 19: 158-164. 10.1016/j.semcancer.2009.02.012View ArticlePubMedGoogle Scholar
- Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J: Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta 2010, 1799: 228-235.View ArticlePubMedGoogle Scholar
- Li MJ, Maizels N: Activation and targeting of immunoglobulin switch recombination by activities induced by EBV infection. J Immunol 1999, 163: 6659-6664.PubMedGoogle Scholar
- Perkins RS, Sahm K, Marando C, Dickson-Witmer D, Pahnke GR, Mitchell M, Petrelli NJ, Berkowitz IM, Soteropoulos P, Aris VM, et al.: Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR. Breast Cancer Res 2006, 8: R70. 10.1186/bcr1627PubMed CentralView ArticlePubMedGoogle Scholar
- Yasui Y, Potter JD, Stanford JL, Rossing MA, Winget MD, Bronner M, Daling J: Breast cancer risk and "delayed" primary Epstein-Barr virus infection. Cancer Epidemiol Biomarkers Prev 2001, 10: 9-16.PubMedGoogle Scholar
- Arbach H, Viglasky V, Lefeu F, Guinebretiere JM, Ramirez V, Bride N, Boualaga N, Bauchet T, Peyrat JP, Mathieu MC, et al.: Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol 2006, 80: 845-853. 10.1128/JVI.80.2.845-853.2006PubMed CentralView ArticlePubMedGoogle Scholar
- Huang J, Chen H, Hutt-Fletcher L, Ambinder RF, Hayward SD: Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol 2003, 77: 13267-13274. 10.1128/JVI.77.24.13267-13274.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Joshi D, Quadri M, Gangane N, Joshi R: Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women. PLoS One 2009, 4: e8180. 10.1371/journal.pone.0008180PubMed CentralView ArticlePubMedGoogle Scholar
- Labrecque LG, Barnes DM, Fentiman IS, Griffin BE: Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res 1995, 55: 39-45.PubMedGoogle Scholar
- Xue SA, Lampert IA, Haldane JS, Bridger JE, Griffin BE: Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger? Br J Cancer 2003, 89: 113-119. 10.1038/sj.bjc.6601027PubMed CentralView ArticlePubMedGoogle Scholar
- Lake A, Shield LA, Cordano P, Chui DT, Osborne J, Crae S, Wilson KS, Tosi S, Knight SJ, Gesk S, et al.: Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer 2009, 125: 1334-1342. 10.1002/ijc.24502View ArticlePubMedGoogle Scholar
- Osborne J, Lake A, Alexander FE, Taylor GM, Jarrett RF: Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma. Int J Cancer 2005, 116: 646-651. 10.1002/ijc.21036View ArticlePubMedGoogle Scholar
- Levine AJ, Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9: 749-758. 10.1038/nrc2723PubMed CentralView ArticlePubMedGoogle Scholar
- Oren M, Cooks T: NFkappaB and p53: A life and death affair. Cell Cycle 2010., 9:Google Scholar
- Oren M, Rotter V: Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010, 2: a001107. 10.1101/cshperspect.a001107PubMed CentralView ArticlePubMedGoogle Scholar
- zur Hausen H, de Villiers EM: Virus target cell conditioning model to explain some epidemiologic characteristics of childhood leukemias and lymphomas. Int J Cancer 2005, 115: 1-5. 10.1002/ijc.20905View ArticlePubMedGoogle Scholar
- Hjalgrim H, Rostgaard K, Johnson PC, Lake A, Shield L, Little AM, Ekstrom-Smedby K, Adami HO, Glimelius B, Hamilton-Dutoit S, et al.: HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci USA 2010, 107: 6400-6405. 10.1073/pnas.0915054107PubMed CentralView ArticlePubMedGoogle Scholar
- Tedeschi R, Bloigu A, Ogmundsdottir HM, Marus A, Dillner J, dePaoli P, Gudnadottir M, Koskela P, Pukkala E, Lehtinen T, Lehtinen M: Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring. Am J Epidemiol 2007, 165: 134-137.View ArticlePubMedGoogle Scholar
- Tedeschi R, Pin E, Martorelli D, Bidoli E, Marus A, Pratesi C, Bortolin MT, Zanussi S, Vaccher E, Dolcetti R, De Paoli P: Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity. Clin Vaccine Immunol 2007, 14: 435-441. 10.1128/CVI.00466-06PubMed CentralView ArticlePubMedGoogle Scholar
- Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA: The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009, 5: e1000496. 10.1371/journal.ppat.1000496PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.